EKSO Bionics Files 8-K on Operations & Financial Condition

TL;DR

**EKSO just filed an 8-K about its financials and other events, so expect news soon.**

AI Summary

Ekso Bionics Holdings, Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial performance and other significant happenings, though the specific details of these events are not included in this summary filing. For investors, this matters because it signals that important financial or operational news from Ekso Bionics is either imminent or has just occurred, which could impact the stock's valuation.

Why It Matters

This filing indicates Ekso Bionics is updating the market on its financial health and other key events, which could influence investor sentiment and stock price.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the lack of specific details about the 'Results of Operations and Financial Condition' or 'Other Events' creates uncertainty, which can be a medium risk.

Analyst Insight

A smart investor would monitor for subsequent filings or press releases from Ekso Bionics Holdings, Inc. that provide the specific details regarding the 'Results of Operations and Financial Condition' and 'Other Events' mentioned in this 8-K, as these will contain the actionable financial information.

Key Numbers

• 20240104 — Date of Report (The date of the earliest event reported in the 8-K filing.)
• 101 Glacier Point, Suite A San Rafael California 94901 — Business Address (The principal executive offices of Ekso Bionics Holdings, Inc.)
• 510-984-1761 — Registrant's telephone number (Contact number for Ekso Bionics Holdings, Inc.)
• $0.001 — par value per share (The par value of Ekso Bionics' Common Stock.)
• 0001549084 — Central Index Key (CIK) (Unique identifier for Ekso Bionics Holdings, Inc. with the SEC.)

Key Players & Entities

• EKSO BIONICS HOLDINGS, INC. (company) — the registrant filing the 8-K
• Nevada (company) — state of incorporation for Ekso Bionics Holdings, Inc.
• Nasdaq Capital Market (company) — exchange where Ekso Bionics' Common Stock is registered
• 001-37854 (dollar_amount) — Commission File Number
• 99-0367049 (dollar_amount) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capi
• $4.7 million — 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared to $3.6 milli
• $4.9 m — d to be in the range of $4.7 million to $4.9 million, compared to $3.6 million for the
• $3.6 million — .7 million to $4.9 million, compared to $3.6 million for the fourth quarter of 2022.  
• $18.1 million — 2023 is estimated to be in the range of $18.1 million to $18.3 million, compared to $12.9 mil
• $18.3 m — to be in the range of $18.1 million to $18.3 million, compared to $12.9 million for fi
• $12.9 million — 1 million to $18.3 million, compared to $12.9 million for fiscal year 2022.    
• $8.6 m — s of December 31, 2023 was an estimated $8.6 million, compared to $20.5 million at Dec
• $20.5 million — an estimated $8.6 million, compared to $20.5 million at December 31, 2022.    
• $1.7 million — of 2023, the Company used an estimated $1.7 million of cash in operations, compared to $3.6

Filing Documents

• ekso20240104_8k.htm (8-K) — 35KB
• ex_612268.htm (EX-99.1) — 11KB
• logo.jpg (GRAPHIC) — 4KB
• 0001437749-24-000621.txt ( ) — 186KB
• ekso-20240104.xsd (EX-101.SCH) — 3KB
• ekso-20240104_def.xml (EX-101.DEF) — 11KB
• ekso-20240104_lab.xml (EX-101.LAB) — 15KB
• ekso-20240104_pre.xml (EX-101.PRE) — 11KB
• ekso20240104_8k_htm.xml (XML) — 3KB

02           Results of Operations and Financial Condition

Item 2.02           Results of Operations and Financial Condition   On January 4, 2024, Ekso Bionics Holdings, Inc. (the "Company") issued a press release (the "Press Release") announcing certain preliminary financial results for the quarter and year ended December 31, 2023. The full text of the Press Release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.   The information contained in Item 2.02 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, and such information shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.    

01           Other Events

Item 8.01           Other Events   In the Press Release, the Company reports the following preliminary financial results:     Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared to $3.6 million for the fourth quarter of 2022.     Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million, compared to $12.9 million for fiscal year 2022.     Estimated cash as of December 31, 2023 was an estimated $8.6 million, compared to $20.5 million at December 31, 2022.     For the fourth quarter of 2023, the Company used an estimated $1.7 million of cash in operations, compared to $3.6 million for the fourth quarter of 2022.   The estimated, projected or anticipated financial results, financial condition or other financial information discussed in this Current Report on Form 8-K are based on management's preliminary unaudited analysis of financial results for the period and year ended December 31, 2023. As of the date of this Current Report on Form 8-K, the Company has not completed its financial statement reporting process for the period ended December 31, 2023, and the Company's independent registered accounting firm has not audited the preliminary financial data discussed in this Current Report on Form 8-K. During the course of the Company's quarter-end closing procedures and review process, including the finalization of its financial statements for and as of the period and year ended December 31, 2023, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary results.  

Forward-Looking Statements

Forward-Looking Statements   Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the estimated financial results. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company's finalization of its financial statements for and as of the period and year ended December 31, 2023, information or new changes in facts or circumstances that may occur prior to the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2023 that are required to be included in such annual report and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statements made in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K. The Company does not undertake to update these forward-looking statements, except as required by la

01           Financial Statements and Exhibits

Item 9.01           Financial Statements and Exhibits   (d) Exhibits     Exhibit   Description   99.1   Press release, dated January 4, 2024   104   Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   EKSO BIONICS HOLDINGS, INC. By: /s/  Jerome Wong Name: Jerome Wong Title: Chief Financial Officer           Dated: January 4, 2024      

View Full Filing

View this 8-K filing on SEC EDGAR